AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in congestive heart failure
|
25 April 2024 |
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson's disease
|
16 April 2024 |
Bayer and Thermo Fisher Scientific collaborate to increase patient access to precision cancer medicines
|
20 March 2024 |
Bayer and Aignostics to collaborate on next generation precision oncology
|
15 March 2024 |
Bayer receives U.S. FDA Breakthrough Therapy designation for BAY 2927088 for non-small cell lung cancer harboring HER2 activating mutations
|
27 February 2024 |
First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure
|
15 February 2024 |
Vividion Therapeutics starts Phase I clinical trial in advanced solid and hematologic tumors with oral STAT3 inhibitor
|
07 February 2024 |
Bayer aims to sustainably improve performance with new organization
|
23 January 2024 |
Bayer's AskBio initiates Phase II GenePHIT trial in Congestive Heart Failure (CHF)
|
12 January 2024 |
AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson's disease meets primary endpoint
|
04 January 2024 |
Bayer and Salus Optima partner on AI-enabled healthy aging journey
|
07 December 2023 |
Bayer and Hurdle launch precision health strategic partnership
|
29 November 2023 |
Bayer invests 130 million EUR in new production facility for innovative parenteral products
|
23 November 2023 |
Bayer and Recursion focus research collaboration on oncology
|
10 November 2023 |
Bayer expands global life science incubator network
|
07 November 2023 |
Bayer and Broad Institute of MIT and Harvard extend research collaboration to develop new cancer therapies
|
02 November 2023 |
AskBio contribution to advancing gene therapy highlighted at ESGCT 30th Congress
|
25 October 2023 |
Bayer invests 250 million USD in new cell therapy manufacturing facility in the U.S.
|
11 October 2023 |
Bayer to partner with Twist Bioscience to accelerate drug discovery
|
05 October 2023 |
Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator
|
18 September 2023 |